A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
To access this article, please choose from the options below
Some of the results presented in this article were previously published in abstract form in Gastroenterology 2007;132(Suppl 2):A-51.
Centocor, Inc (Malvern, PA) provided support for this study (C0379T07; clinical trials registration: clinicaltrials.gov #NCT00265122). Marion Blank and Jewel Johanns are employees of Centocor, Inc; William J. Sandborn received research funding in conjunction with the conduct of this study, he also received a research grant (1-UL1-RR024150-01) from the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research and is a consultant to Centocor, Inc (fees paid to the Mayo Clinic); Brian G. Feagan received research funding in conjunction with the conduct of this study, he also received other research grants and is a consultant to Centocor, Inc; Richard N. Fedorak received research funding in conjunction with the conduct of this study; Ellen Scherl received research funding in conjunction with the conduct of this study and other research grants and served as a consultant to Centocor, Inc; Mark R. Fleischer received research funding in conjunction with the conduct of this study and speaker payments, and has served as a consultant to Centocor, Inc; Seymour Katz received research funding in conjunction with the conduct of this study and other research grants from Centocor, Inc; Paul Rutgeerts received research funding in conjunction with the conduct of this study, he also received other research grants and speaker payments, and is a consultant to Centocor, Inc.
Members of the Ustekinumab Crohn's Disease Study Group are listed at the end of the article.
PII: S0016-5085(08)01322-X
doi:10.1053/j.gastro.2008.07.014
© 2008 AGA Institute. Published by Elsevier Inc. All rights reserved.

